Comparative Pharmacology
Head-to-head clinical analysis: QUINALAN versus QUINATIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINALAN versus QUINATIME.
QUINALAN vs QUINATIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
None Documented
None Documented
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)